Cargando…
Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial
BACKGROUND: A dichotomous index combining two gene expression assays, HOXB13 : IL17BR (H : I) and molecular grade index (MGI), was developed to assess risk of recurrence in breast cancer patients. The study objective was to demonstrate the prognostic utility of the combined index in early-stage brea...
Autores principales: | Jerevall, P-L, Ma, X-J, Li, H, Salunga, R, Kesty, N C, Erlander, M G, Sgroi, D C, Holmlund, B, Skoog, L, Fornander, T, Nordenskjöld, B, Stål, O |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111159/ https://www.ncbi.nlm.nih.gov/pubmed/21559019 http://dx.doi.org/10.1038/bjc.2011.145 |
Ejemplares similares
-
Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010) -
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease
por: Habel, Laurel A, et al.
Publicado: (2013) -
Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013) -
HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation
por: Jung, C, et al.
Publicado: (2005) -
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
por: Karlsson, Elin, et al.
Publicado: (2013)